The Lancet publishes KEYNOTE-942 Phase 2b results of intismeran plus Keytruda in resected melanoma

Moderna/Intismeran autogene (mRNA-4157/V940)

The Lancet published KEYNOTE-942 Phase 2b results: in 157 patients with resected high-risk melanoma, adding the personalised mRNA vaccine intismeran to Keytruda raised 18-month recurrence-free survival to 79% from 62%, with hazard ratio 0.561 narrowly missing conventional significance (p=0.053).

• Intismeran (mRNA-4157/V940) is a neoantigen vaccine tailored to each patient's tumor mutations.
• Combination with Keytruda (pembrolizumab) showed 18% absolute improvement in RFS at 18 months.
• Study enrolled 157 patients with stage IIB-IV melanoma; combination arm had lower recurrence/death risk.
• p=0.053 misses p<0.05 statistical threshold but represents substantial clinical benefit; Lancet publication acknowledges significance.